• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

NCI-MATCH precision medicine trial reaches milestone

Bioengineer by Bioengineer
May 30, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

NCI-MATCH (Molecular Analysis for Therapy Choice), the largest precision medicine trial of its kind, achieves a milestone with the release of results from three treatment arms of the trial at the American Society of Clinical Oncology (ASCO) 2018 annual meeting. Spokespersons are available for interviews.

The new results offer findings of interest for future cancer research. They could help identify targeted treatments for patients with certain gene abnormalities regardless of their cancer type. The results are the first of a large trove of data to come from nearly 40 treatment arms in new populations of patients not yet studied in any other clinical trials.

NCI-MATCH is a signal-finding trial for adults who have solid tumors, lymphomas, or myeloma that have progressed on standard treatment or rare cancers for which there is no standard treatment. The trial was co-developed by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group, part of the NCI-sponsored National Clinical Trials Network (NCTN). ECOG-ACRIN is leading the trial.

###

WHO: Sub-study chairs and primary trial chairs from NCI and ECOG-ACRIN

WHAT: Patient outcomes data from NCI-MATCH

WHEN: Friday, June 1, 2:45 p.m. Abstract 2503. AZD4547 in tumors with FGFR pathway aberrations (Arm W)

Saturday, June 2, 8:00 a.m. Abstract 100. T-DM1 in tumors with HER2 gene amplification (Arm Q).

And Abstract 101. Taselisib in tumors with PIK3CA gene mutations (Arm I)

WHERE: ASCO 2018 Annual Meeting, McCormick Place, Chicago

To schedule an interview with a spokesperson about NCI-MATCH prior to or during the ASCO Annual Meeting, use the contact information above.

Media Contact

Diane M Dragaud
[email protected]
215-789-3631
@eaonc

Home

http://ecog-acrin.org/news-and-information/press-releases/first-patient-outcomes-data

Share12Tweet7Share2ShareShareShare1

Related Posts

Synthetic Image Learning: A New Federated Alternative

October 23, 2025

Filipino Seniors’ Dietary Patterns and Influencing Factors

October 23, 2025

Almost 20% of Urinary Tract Infections Traced to Contaminated Meat, Study Finds

October 23, 2025

Understanding Parents’ Needs in Pediatric Emergency Care

October 23, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1276 shares
    Share 510 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    307 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    162 shares
    Share 65 Tweet 41
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    132 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Synthetic Image Learning: A New Federated Alternative

Filipino Seniors’ Dietary Patterns and Influencing Factors

FAU Engineering Innovators Achieve Significant Advances in Gait Analysis Technology

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.